StockCall.com Provides Stock Research on GlaxoSmithKline plc, AstraZeneca PLC, Keryx Biopharmaceuticals Inc., and Raptor Pharmaceuticals Corp.
New York City, New York -- (May 02, 2013)
Major drug manufacturers have reported their financial results for the first quarter during the latest earnings season. The results highlight the challenge major drug manufacturers are facing from generic competition. Most major drug manufacturers have seen their revenue miss estimates. With patents on several blockbuster drugs set to expire this year as well, drug manufacturers will remain under pressure. Shares of drug manufacturers ended mostly lower on Wednesday as the broad market tumbled following some weak economic data. Among the major movers were GlaxoSmithKline Plc (NYSE: GSK), AstraZeneca Plc (NYSE: AZN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at
www.stockcall.com/report
Shares of GlaxoSmithKline Plc edged lower on Wednesday, extending their losses for the week. The stock closed 0.27% lower at $51.50 on volume of 2.22 million, taking its losses in the last three trading sessions to over 1.20%. Despite the recent pullback, shares of GSK are currently trading close to their 52-week high of $52.54. The stock has seen a series of highs over the last two months which is a bullish signal. However, the stock’s MACD chart suggests that market sentiment has turned bearish recently. Year-to-date, GlaxoSmithKline’s shares have gained more than 20.20%. Sign up for the free report on GSK at
www.StockCall.com/GSK050213.pdf
Shares of AstraZeneca Plc also slipped in yesterday’s session. The stock traded between $51.53 and $52.05 before finishing the day 0.64% lower at $51.59 on volume of 1.17 million. AstraZeneca’s shares are currently trading 1.24% below their 52-week high. The stock has outperformed the S&P 500 so far in 2013, gaining nearly 13.70%. However, the stock’s MACD is currently trading below the signal line which suggests that market sentiment is bearish on the stock. Shares of AZN currently have support at around $51. AZN free technical report can be accessed by signing up at
www.StockCall.com/AZN050213.pdf
Shares of Keryx Biopharmaceuticals Inc. fell sharply in trading on Wednesday, tracking losses in the broad market. The stock ended the day 4.18% lower at $7.81 on volume of 2.36. Despite the sharp decline yesterday, Keryx’s shares are still up more than 198% thus far in 2013. Most of the stock’s gains for the year came in late January when it saw a huge rally. Since the rally, the company’s shares have traded sideways, struggling to break through $8.50 resistance level. The stock currently has strong support at around $7.50. Free report on KERX can be accessed by registering at
www.StockCall.com/KERX050213.pdf
Shares of Raptor Pharmaceutical Corp. also struggled in yesterday’s trading session. The stock traded between $6.62 and $7.20 before finishing the day 3.19% lower at $6.68 on above average volume of 2.14 million. In spite of the sharp decline, Raptor Pharmaceutical’s shares are still up 0.15% for the week. Year-to-date, the stock has gained nearly 14.20%, outperforming the S&P 500. The company’s shares are also trading well above their 50-day and 200-day moving averages. The stock had seen a series of highs last week which is a bullish signal.Register withStockCall and download the research on RPTP for free at
www.StockCall.com/RPTP050213.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
www.stockcall.com
Contact Person:
William T. Knight
Email:info@stockcall.com
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)